SAB Biotherapeutics closed at $3.18 on Nov 4, up 1.92%, 30.7% below its 52-week closing high. Volume of 1.0M shares was 1.61× its 20-day average (above normal).
Split-adjusted performance: +8.5% over one month, -16.3% over six months, -2.2% over one year.
Short interest was 4.8M shares at the Oct 15 settlement, up 11.9% from the prior report (6.2% of float, 6.9 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SABSSAB Biotherapeutics | $3.18 | +1.92% | −16.3% | — | — | — | $289.3M | |
| OCGNOcugen | $0.8745 | +17.35% | −39.9% | +8.4% | −1671.8% | — | $296.6M | Compare |
| IPSCCentury Therapeutics | $1.67 | +9.87% | −28.6% | — | — | — | $302.4M | Compare |
| AGENAgenus | $6.97 | +4.50% | +79.2% | +34.4% | −1.7% | 3.4 | $314.8M | Compare |
| LXEOLexeo Therapeutics | $3.23 | +3.86% | −48.2% | — | — | — | $265.1M | Compare |
| SCTXScribe Therapeutics | $16.78 | +3.58% | — | — | — | — | $317.7M | Compare |
| KYTXKyverna Therapeutics | $5.16 | 0.00% | −45.5% | — | — | — | $319.1M | Compare |
| XFORX4 Pharmaceuticals | $3.24 | +2.21% | −26.0% | +346.3% | −183.5% | — | $321.2M | Compare |
| LCTXLineage Cell Therapeutics | $1.03 | +1.98% | −28.0% | −61.3% | 138.6% | — | $260.5M | Compare |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
